S&P 500   4,550.29 (+0.39%)
DOW   35,178.93 (+0.43%)
QQQ   368.57 (+0.57%)
AAPL   166.71 (+0.29%)
MSFT   306.90 (+1.18%)
FB   322.16 (+0.80%)
GOOGL   2,717.76 (+0.57%)
AMZN   3,105.44 (-0.66%)
TSLA   1,018.85 (+2.33%)
NVDA   250.94 (+0.11%)
BABA   132.50 (+3.73%)
NIO   30.02 (+4.86%)
AMD   126.73 (-1.20%)
CGC   7.73 (+1.18%)
MU   87.77 (-2.48%)
GE   100.28 (-0.34%)
T   27.24 (-0.15%)
F   22.11 (-1.51%)
DIS   150.25 (+0.09%)
AMC   18.80 (+2.62%)
PFE   54.14 (+1.12%)
ACB   4.85 (-0.21%)
BA   218.12 (+0.48%)
S&P 500   4,550.29 (+0.39%)
DOW   35,178.93 (+0.43%)
QQQ   368.57 (+0.57%)
AAPL   166.71 (+0.29%)
MSFT   306.90 (+1.18%)
FB   322.16 (+0.80%)
GOOGL   2,717.76 (+0.57%)
AMZN   3,105.44 (-0.66%)
TSLA   1,018.85 (+2.33%)
NVDA   250.94 (+0.11%)
BABA   132.50 (+3.73%)
NIO   30.02 (+4.86%)
AMD   126.73 (-1.20%)
CGC   7.73 (+1.18%)
MU   87.77 (-2.48%)
GE   100.28 (-0.34%)
T   27.24 (-0.15%)
F   22.11 (-1.51%)
DIS   150.25 (+0.09%)
AMC   18.80 (+2.62%)
PFE   54.14 (+1.12%)
ACB   4.85 (-0.21%)
BA   218.12 (+0.48%)
S&P 500   4,550.29 (+0.39%)
DOW   35,178.93 (+0.43%)
QQQ   368.57 (+0.57%)
AAPL   166.71 (+0.29%)
MSFT   306.90 (+1.18%)
FB   322.16 (+0.80%)
GOOGL   2,717.76 (+0.57%)
AMZN   3,105.44 (-0.66%)
TSLA   1,018.85 (+2.33%)
NVDA   250.94 (+0.11%)
BABA   132.50 (+3.73%)
NIO   30.02 (+4.86%)
AMD   126.73 (-1.20%)
CGC   7.73 (+1.18%)
MU   87.77 (-2.48%)
GE   100.28 (-0.34%)
T   27.24 (-0.15%)
F   22.11 (-1.51%)
DIS   150.25 (+0.09%)
AMC   18.80 (+2.62%)
PFE   54.14 (+1.12%)
ACB   4.85 (-0.21%)
BA   218.12 (+0.48%)
S&P 500   4,550.29 (+0.39%)
DOW   35,178.93 (+0.43%)
QQQ   368.57 (+0.57%)
AAPL   166.71 (+0.29%)
MSFT   306.90 (+1.18%)
FB   322.16 (+0.80%)
GOOGL   2,717.76 (+0.57%)
AMZN   3,105.44 (-0.66%)
TSLA   1,018.85 (+2.33%)
NVDA   250.94 (+0.11%)
BABA   132.50 (+3.73%)
NIO   30.02 (+4.86%)
AMD   126.73 (-1.20%)
CGC   7.73 (+1.18%)
MU   87.77 (-2.48%)
GE   100.28 (-0.34%)
T   27.24 (-0.15%)
F   22.11 (-1.51%)
DIS   150.25 (+0.09%)
AMC   18.80 (+2.62%)
PFE   54.14 (+1.12%)
ACB   4.85 (-0.21%)
BA   218.12 (+0.48%)
NASDAQ:VBLT

Vascular Biogenics Stock Forecast, Price & News

$1.45
-0.07 (-4.61%)
(As of 01/20/2022 02:33 PM ET)
Add
Compare
Today's Range
$1.44
$1.53
50-Day Range
$1.52
$2.53
52-Week Range
$1.48
$3.17
Volume
19,622 shs
Average Volume
251,146 shs
Market Capitalization
$90.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.06
30 days | 90 days | 365 days | Advanced Chart
Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.


Vascular Biogenics logo

About Vascular Biogenics

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of first-in-class treatments for cancer. Its programs include cancer, inflammation, and VB-600 which are focused on treating tumors, ovarian cancer, and chronic immune-related indications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Headlines

BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure
December 28, 2021 |  finance.yahoo.com
What Makes Vascular Biogenics (VBLT) a New Buy Stock
November 18, 2021 |  finance.yahoo.com
Vascular Biogenics earnings preview: what Wall Street is expecting
November 15, 2021 |  markets.businessinsider.com
VBL Therapeutics to Present at Upcoming Conferences
September 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBLT
Previous Symbol
NASDAQ:VBLX
Employees
38
Year Founded
N/A

Sales & Book Value

Annual Sales
$920 thousand
Book Value
$0.64 per share

Profitability

Net Income
$-24.23 million
Net Margins
-3,612.61%
Pretax Margin
-3,613.39%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$90.43 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/20/2022
Next Earnings (Estimated)
3/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

986th out of 1,415 stocks

Pharmaceutical Preparations Industry

479th out of 682 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

Is Vascular Biogenics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vascular Biogenics stock.
View analyst ratings for Vascular Biogenics
or view top-rated stocks.

How has Vascular Biogenics' stock price been impacted by COVID-19?

Vascular Biogenics' stock was trading at $1.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VBLT shares have increased by 18.9% and is now trading at $1.45.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 1,630,000 shares, a decrease of 20.9% from the December 15th total of 2,060,000 shares. Based on an average daily trading volume, of 201,800 shares, the short-interest ratio is presently 8.1 days.
View Vascular Biogenics' Short Interest
.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Vascular Biogenics
.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) issued its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. Vascular Biogenics had a negative net margin of 3,612.61% and a negative trailing twelve-month return on equity of 66.02%. During the same period in the prior year, the business earned ($0.12) EPS.
View Vascular Biogenics' earnings history
.

What price target have analysts set for VBLT?

4 brokers have issued 1 year price targets for Vascular Biogenics' stock. Their forecasts range from $4.00 to $7.00. On average, they expect Vascular Biogenics' stock price to reach $5.75 in the next year. This suggests a possible upside of 296.6% from the stock's current price.
View analysts' price targets for Vascular Biogenics
or view top-rated stocks among Wall Street analysts.

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the following people:
  • Dror Harats, Chief Executive Officer & Director
  • Eyal Breitbart, Vice President-Research & Operations
  • Erez Feige, Vice President-Business Operations
  • Samuel I. Backenroth, Chief Financial Officer
  • Tami Rachmilewitz, Vice President-Clinical Development

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Spectrum Planning & Advisory Services Inc. (0.03%).

Which major investors are buying Vascular Biogenics stock?

VBLT stock was purchased by a variety of institutional investors in the last quarter, including Spectrum Planning & Advisory Services Inc..

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.45.

How much money does Vascular Biogenics make?

Vascular Biogenics has a market capitalization of $90.43 million and generates $920 thousand in revenue each year. The biopharmaceutical company earns $-24.23 million in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Vascular Biogenics have?

Vascular Biogenics employs 38 workers across the globe.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is www.vblrx.com.

Where are Vascular Biogenics' headquarters?

Vascular Biogenics is headquartered at 8 HASATAT STREET, MODI IN L3, 7178106.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at [email protected], or via fax at 972-8993-5001.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.